会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 10. 发明授权
    • Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
    • 使用二十二烷,溶血凝素及其稳定的类似物治疗气道疾病和哮喘
    • US07759395B2
    • 2010-07-20
    • US11081203
    • 2005-03-16
    • Charles N. SerhanBruce D. Levy
    • Charles N. SerhanBruce D. Levy
    • A01N37/00
    • C07C59/42A61K31/202A61K31/275A61K31/445A61K31/495A61K31/537A61K31/551A61K31/655C07C59/48C07F7/1804
    • The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
    • 本发明一般涉及由膳食ω-3多不饱和脂肪酸(PUFA)如二十碳五烯酸(EPA)或二十二碳六烯酸(DHA),环氧合酶II(COX)之间的相互作用产生的新型分离的治疗剂,称为溶血素 -2)和止痛剂,例如阿司匹林(ASA)。 令人惊讶的是,在合适的环境中仔细分离由组分组合产生的化合物,提供了具有独特结构和生理特性的二羟基EPA或DHA化合物。 因此,本发明提供了例如减少,预防或消除炎症或PMN迁移的许多新的有用的EPA或DHA(resolvins)治疗二 - 或三羟基衍生物。 本发明还提供了用于本说明书中公开的化合物的药物用途,制备方法和包装药物的方法。